跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2018-002301-61-DE
EUCTR2018-002301-61-DE进行中（未招募）1 期

A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalationand Expansion Study of Gilteritinib (ASP2215) Combined withChemotherapy in Children, Adolescents and Young Adults with FMS-likeTyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD)Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Astellas Pharma Global Development, Inc. (APGD)0 个研究点目标入组 97 人开始时间: 2019年7月16日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
发起方
入组人数
97
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent and privacy language as required per national regulations (e.g., Health Insurance
  • •Portability and Accountability Act Authorization for US sites) must be obtained from the subject or subject’s parent or legal guardian and if required child assent prior to any study-related procedures.
  • •2. Phase 1: Subject is positive for FLT3 (ITD and/or TKD) mutation in bone marrow or blood as determined by the local institution
  • •Phase 2: Subject is positive for the FLT3 (ITD) mutation in bone marrow
  • •or blood as determined by the local institution.
  • •3. Subject is aged = 6 months and < 21 years of age at the time of signing informed consent and/or assent, as applicable.
  • •* For phase 2: Enrollment of subjects from 6 months to less than 1 year (Group 3) and 1 year to less than 2 years (Group 2) will be dependent on the establishment of RP2D in the respective for age groups during phase 1.
  • •4. Subject has a diagnosis of AML according to The French–American–British (FAB) classification with = 5% blasts in the bone marrow, with or without extramedullary disease (except subjects with active central nervous system [CNS] leukemia).
  • •a) In the phase 1 portion of the study, subject must be in first or greater relapse or refractory to induction therapy with no more than 1 attempt at remission induction (up to two induction cycles).
  • •b) For the phase 2 portion of the study, subject must be in first relapse or refractory to induction therapy with no more than 1 attempt at remission induction (up to 2 induction cycles).
  • •5.Subject has fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
  • •6. For subject undergoing hematopoietic stem cell transplant (HSCT), at least 90 days must have elapsed since HSCT and subject must not have active graft-versus-host disease (GVHD).
  • •7. Subject has Karnofsky score = 50 (if the subject is of = 16 years of age) or Lansky score of = 50 (if the subject is < 16 years of age). A score < 50 is acceptable if related to the subject's leukemia in the investigators judgment.
  • •8. Subject must meet the following criteria as indicated on the clinical
  • •laboratory tests.
  • •Serum AST and ALT = 3.0 x upper limit normal (ULN) for age
  • •Total serum bilirubin = 1.5 x ULN for age
  • •Estimated glomerular filtration rate of > 60 mL/min/1.73 m2.
  • •9. A female subject is eligible to participate if she is not pregnant and at least 1 of the following conditions applies:
  • •a) Not a woman of childbearing potential (WOCBP) as defined in [Appendix 12.3 Contraception Requirements]
  • •b) WOCBP who agrees to follow the contraceptive guidance as defined in throughout the treatment period and for at least 180 days after the final study drug administration.
  • •10. Female subject must agree not to breastfeed starting at Screening, and throughout the study period and for 60 days after the final study drug administration.
  • •11. Female subject must not donate ova starting at Screening and throughout the study, and for 180 days after the final study drug administration.
  • •12.A male subject with female partner(s) of childbearing potential must agree to use contraception as detailed in [Appendix 12.3 Contraception Requirements] during the treatment period and for at least 180 days after the final study drug administration.
  • •13. A male subject must not donate sperm during the treatment period and for at least 120 days after the

排除标准

  • •1. Subject has active CNS leukemia.
  • •2. This criterion has been removed.
  • •3. Subject has uncontrolled or significant cardiovascular disease, including:
  • •-Diagnosed or suspected congenital long QT syndrome or any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or TdPtorsades de pointes); any history of arrhythmia will be discussed with the sponsor’s medical monitor prior to subject’s entry into the study
  • •- Prolonged QTcF interval on pre-entry ECG (= 450 ms)
  • •- Any history of second or third degree heart block (may be eligible if the subject currently has a pacemaker)
  • •- Heart rate < 50 beats/minute on pre-entry ECG
  • •- Uncontrolled hypertension
  • •- Complete left bundle branch block
  • •4. Subject has systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. The subject needs to be off pressors and have negative blood cultures for 48 hours.
  • •5. Subject is receiving or plans to receive concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
  • •6. Subject has active clinically significant GVHD or is on treatment with immunosuppressive drugs for treatment of active GVHD, with the exception of subjects being weaned from systemic corticosteroids where the subjects is receiving = 0.5 mg/kg of prednisone (or equivalent) daily dose for prior GVHD. Subjects has received calcineurin inhibitors within 4 weeks prior to screening unless used as GVHD prophylaxis.
  • •7. Subject has active malignant tumors other than AML.
  • •8. Subject has any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise subject safety or compliance; interfere with consent, study participation, follow-up or interpretation of study results.
  • •9. Subject has hypokalemia and/or hypomagnesemia at Screening (defined as values below institutional lower limit of normal [LLN]). Repletion of potassium and magnesium levels during the screening period is allowed.
  • •10. Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A/P-glycoprotein (P-gp).
  • •11. Subject is known to have human immunodeficiency virus infection.
  • •12. Subject has active hepatitis B or C, or other active hepatic disorder.
  • •? Subjects with positive hepatitis B surface antigen (HBsAg) or detectable hepatitis B DNA are not eligible.
  • •? Subjects with negative HBsAg, positive hepatitis B core antibody and negative hepatitis B surface antibody will be eligible if hepatitis B DNA undetectable.
  • •? Subjects with antibodies to hepatitis C virus will be eligible if hepatitis C RNA is undetectable.
  • •13. This criterion has been removed.
  • •14. Subject must wait for at least 5 half-lives after stopping therapy with any investigational agent and before starting gilteritinib.
  • •15. Subject has known or suspected hypersensitivity to gilteritinib, cytarabine, fludarabine, G-CSF or any components of the formulations used.

研究者

发起方
Astellas Pharma Global Development, Inc. (APGD)

相似试验

已完成
2 期
A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML) with a FLT3 gene mutation
2024-512469-15-00Astellas Pharma Global Development Inc.45
招募中
1 期
A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML) with a FLT3 gene mutatio
CTIS2024-512469-15-00Astellas Pharma Global Development Inc.97
进行中（未招募）
1 期
A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML) with a FLT3 gene mutation.FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864
EUCTR2018-002301-61-ITASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.114
进行中（未招募）
1 期
A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML) with a FLT3 gene mutatioFMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed orRefractory Acute Myeloid Leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864
EUCTR2018-002301-61-GBAstellas Pharma Global Development, Inc. (APGD)114
进行中（未招募）
1 期
A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects with Acute Myeloid Leukemia who are 60 Years or Older - The BATTLE StudyAcute Myeloid Leukemia
EUCTR2017-002237-29-SKBioLineRx, Ltd.60